European Union - English - EMA (European Medicines Agency)

abbvie ltd - ombitasvir / paritaprevir / ritonavir - hepatitis c, chronic - antivirals for systemic use - viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.

European Union - English - EMA (European Medicines Agency)

abbvie ltd - dasabuvir sodium - hepatitis c, chronic - antivirals for systemic use, - exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults. for hepatitis c virus (hcv) genotype specific activity.,

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dksh agrisolutions pty ltd - direct red 254 - unknown - direct red 254 dye active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

direct safety - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - purpose pain reliever/fever reducer uses temporarily relieves ■ headache ■ muscle pain ■ toothache ■ menstrual pain ■ pain and fever of colds ■ minor pain of arthritis do not use if you are allergic to aspirin or to any other pain reliever/fever reducer stop use and ask a doctor if ■ an allergic reaction occurs. seek medical help right away. ■ you experience any of the following signs of stomach bleeding: ■ feel faint ■ vomit blood ■ have bloody or black stools ■ have stomach pain that does not get better ■ pain gets worse or lasts more than 10 days ■ fever lasts more than 3 days ■ if ringing in the ears or loss of hearing occurs ■ redness or swelling is present ■ new symptoms occur

European Union - English - EMA (European Medicines Agency)

janssen-cilag international nv - simeprevir - hepatitis c, chronic - antivirals for systemic use - olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult patients.for hepatitis c virus (hcv) genotype specific activity.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - hepatitis c, chronic - antivirals for systemic use - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults (see sections 4.2, 4.4 and 5.1). for hcv genotype specific activity, see sections 4.4 and 5.1.,

European Union - English - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir - hepatitis c, chronic - antivirals for systemic use - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).for hepatitis c virus (hcv) genotype specific activity, see sections 4.4 and 5.1.sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).for hepatitis c virus (hcv) genotype specific activity, see sections 4.4 and 5.1.

European Union - English - EMA (European Medicines Agency)

gilead sciences ireland uc - ledipasvir, sofosbuvir - hepatitis c, chronic - antivirals for systemic use - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).for hepatitis c virus (hcv) genotype-specific activity see sections 4.4 and 5.1.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - lopinavir (amorphous); ritonavir - film coated tablet - 200/50 milligram - direct acting antivirals

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - elbasvir, grazoprevir - hepatitis c, chronic - direct acting antivirals, antivirals for systemic use, , antivirals for treatment of hcv infections - zepatier is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1). for hepatitis c virus (hcv) genotype-specific activity see sections 4.4 and 5.1.,